Scientific Posters and Presentations

Acute Care

APONVIE™

Amy Yamamoto, Chris Storgard, Nancy Yuan, Thomas Ottoboni. Phase 1 Bioavailability Study of HTX-019 Intravenous Injection Compared with Aprepitant Oral Capsules. Presented at the American Society of Anesthesiology 2022 Meeting, October 21-25, 2022.

ZYNRELEF^®

Geibel P, Yuan N, Yamamoto A, et al. Safety, Pharmacokinetics, and Analgesic Activity of HTX-011 in Spinal Surgery. ePoster #48 presented at the Southern Orthopedic Association’s (SOA) Annual Meeting, July 26-29, 2023.

Cusick M, Yuan N, Yamamoto A, et al. Safety, Pharmacokinetics, and Analgesia of HTX-011 in Total Shoulder Arthroplasty. Presented at the Southern Orthopedic Association’s (SOA) Annual Meeting, July 26-29, 2023

John Fanikos, Jackie Evans-Shields, Nancy Yuan, Francesco Palazzo, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Heron Therapeutics, Inc., San Diego, CA, Jefferson Methodist Hospital, Thomas Jefferson University, Philadelphia, PA. Opioid-Free Recovery after Inguinal Hernia Repair with Bupivacaine and Meloxicam Extended-Release Solution (ERBMS) as the Foundation of a Multimodal Analgesia Regimen in a Real-World Setting . Presented at ASHP Annual Meeting 2022, Las Vegas.

Craig Saffer, Chris Storgard, Katie Luepke, Timothy Melson. Interim Safety and Efficacy of HTX-011 Administered Postpartum to Women Undergoing a Planned Caesarean Section. Presented at the 54th Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Chicago, IL, May 2022.

Charles Luke, Francesco Palazzo, Phillip Shadduck, John Fanikos, Jia Hu. Opioid-Free Inguinal Hernia Repair with a Non-Opioid, Multimodal Analgesia (MMA) Regimen Including HTX-011 in a Real-World Setting. Presented at the 2021 ASRA 20th Annual Pain Medicine Meeting, November 18-20 2021.

Sculco P, Pollak R, Rudolph R, et al. No Evidence of Bone-Healing Impairment or NSAID-Related Toxicity With (ZYNRELEF) HTX-011. Presented at the Eastern Orthopaedic Association (EOA) Annual Meeting, October 20-23, 2021.

John Fanikos, Charles Luke, Phillip Shadduck, Francesco Palazzo, Jia Hu. Opioid-Free Recovery After Inguinal Hernia Repair With HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting.

Minkowitz H, Luke C, Hardman D, Hu J. Overall Safety Of HTX-011 When Used With Scheduled Non-Opioid NSAID-containing Multimodal Analgesia (MMA). Presented at the American Society of Anesthesiologists Annual Meeting, Oct 9-12, 2021.

Hacker, Peter Gerner, Jia Hu, Alan Rechter. Total Knee Arthroplasty Pain Management With HTX-011 as the Foundation of a Multimodal Analgesic Regimen Results in Low Incidence of Severe Pain Scott. Presented at AAOS 2021, September 2021

“Encore Presentation”. Scott Hacker, Pamela Hawn, Jia Hu, Alan Rechter. Safety of HTX-011 in Patients ≥65Years Old as Part of a Postoperative Multimodal Analgesia Regimen. Presented at Orthopedics Today, August 2021.

Taras Grosh, Pamela Hawn, Jia Hu, Alex Bekker. Safety of HTX-011 in Patients ≥65 Years Old as Part of a Postoperative Multimodal Analgesia Regimen. Presented at ASRA 2021, August 2021.

Yamamoto A, Wilker C, Griffith A, Brantley S, Saffer C. Concentrations of bupivacaine and meloxicam in breast milk after exposure to HTX-011. Presented at the American Society of Health-System Pharmacists (ASHP) Midyear 2020 Congress, December 6-10, 2020.

Viscusi E, Minkowitz H, Hu J. HTX-011. No evidence of local anesthetic systemic toxicity. Presented at American Society of Regional Anesthesia and Pain Medicine (ASRA) Worldwide 2020, 19th Annual Pain Medicine Meeting. November 20-22, 2020.

Luke C, Saleh J, Hardman D, Ottoboni T. HTX-011: Predictable release rates of bupivacaine and meloxicam for 72 hours. Presented at American Society of Regional Anesthesia and Pain Medicine (ASRA) Worldwide 2020, 19th Annual Pain Medicine Meeting. November 20-22, 2020

Lachiewicz P, Lee G-C, Cromer A, Sharma A, Dai D. Opioid-naïve patients are susceptible to prolonged opioid use and costs after primary total knee arthroplasty. Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons, November 5-8, 2020.

Luke C, Saleh J, Hardman D, Ottoboni T. HTX-011: Predictable Release Rates of Bupivacaine and Meloxicam for 72 Hours. Presented at the American Society of Anesthesiologists (ASA) Annual Meeting; October 2-5, 2020.

Viscusi E, Minkowitz H, Hu J. HTX-011: HTX-011: No Evidence of Local Anesthetic Systemic Toxicity. Presented at the American Society of Anesthesiologists (ASA) Annual Meeting; October 2-5, 2020.

Lee G, Cai D. Opioid-Free Postoperative Pain Management in Patients Undergoing Bunionectomy With the Extended-Release Analgesic HTX-011. Presented at the American Academy of Orthopedic Surgeons (AAOS) Congress; March 24-28, 2020.

Hacker S. Postoperative pain management of total knee arthroplasty using HTX-011 with multimodal analgesia: results from a phase 3b open-label study. Presented at Orthopedics Today Hawaii 2020 CME Meeting, January 12-16, 2020, Kauai, HI.

Evans-Shields J, Viscusi E, Minkowitz H, Winkle P, Hu J, Singla N. Opioid-free Postoperative Recovery in Patients Undergoing Herniorrhaphy With HTX-011 as the Foundation of a Scheduled, Non-opioid Multimodal Analgesic Regimen. Presented at the American Society of Health-System Pharmacists (ASHP) Midyear 2019 Congress, December 8-12, 2019, Las Vegas, NV.

Fanikos J, Minkowitz H, Reinhorn M, Quart B. HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesic Regimen Reduces the Need for Opioids Following Herniorrhaphy in a Real-World Study. Presented at the American Society of Health-System Pharmacists (ASHP) Midyear 2019 Congress, December 8-12, 2019, Las Vegas, NV.

Hu J, Pollak R, Evans-Shields J, Lee GC. Opioid-free Postoperative Recovery in Patients Undergoing Bunionectomy With HTX-011, an Extended-Release Local Anesthetic. Presented at the American Society of Health-System Pharmacists (ASHP) Midyear 2019 Congress, December 8-12, 2019, Las Vegas, NV.

Singla N, Quart B, Evans-Shields J, Hu J, Redan J. Reduction in Proportion of Patients With Severe Pain Following Herniorrhaphy Using HTX-011 as the Foundation of a Non-Opioid Multimodal Analgesic Regimen. Presented at the European Society of Regional Anaesthesia & Pain Therapy (ESRA) 2019 Congress; September 2019.

Yamamoto A, Ottoboni T, Quart B. Pharmacokinetics and Safety of Different Bupivacaine Formulations and Administration Techniques in Augmentation Mammoplasty. Presented at the American Society of Health-system Pharmacists (ASHP) 2019 Congress, June 8-12, 2019, Boston, MA.

Singla N, Hu J, Redan J. Opioid-Free Hernia Recovery With HTX-011, the First Dual-Acting Local Anesthetic, as Foundation Therapy. Presented at the American Society for Enhanced Recovery and Perioperative Medicine (ASER) 2019 Congress, April 25-27, 2019, Washington, DC.

Viscusi E, Minkowitz H, Onel E, Chu A, Patel SS, Ottoboni T, Wilker C, Quart B. Synergistic Effect of the Active Components in HTX-011, a Novel Fixed-ratio Formulation of Bupivacaine and Meloxicam, Across Multiple Doses and Surgical Models. Presented at ASRA Spring 2018, April 2018.

Viscusi E, DeLeon-Casasola O, Gan TJ, Onel E, Boccia G, Chu A, Keller MR, Ottoboni T, Patel SS, Quart B. HTX-011, a proprietary, unique, long-acting local anesthetic, reduces acute postoperative pain intensity and opioid consumption following bunionectomy. Presented at Clinical Congress 2017, October 2017.

Leiman D, Minkowitz HS, Patel SS, Boccia G, Chu A, Heiner L, Keller MR, Onel E, Ottoboni T, Quart B. HTX-011, a proprietary, unique, long-acting local anesthetic, reduces acute postoperative pain intensity and opioid consumption following abdominoplasty. Presented at Clinical Congress 2017, October 2017.

Onel E, Chu A, Patel SS, Ottoboni T, Wilker C, Quart B. Synergistic effect of bupivacaine and meloxicam in HTX-011 across multiple doses and surgeries. Presented at ACCP 2017 Annual Meeting, October 2017.

Viscusi E, Onel E, Boccia G, Chu A, Keller MR, Ottoboni T, Patel SS, Cravets M, Manhard K, Quart B. HTX-011, A locally administered analgesic, reduces postoperative pain intensity and opioid use through 72 hours across bony and soft tissue surgical models. Presented at the European Society of Regional Anaesthesia & Pain Therapy (ESRA) 2017 Annual Congress, September 2017.

Ottoboni T, Wilker C, Onel E, Chu A, Patel SS, Quart B. Synergistic effect of bupivacaine and meloxicam in HTX-011: animal and clinical studies. Presented at the IARS 2017 Annual Meeting and International Science Symposium, May 2017.

Leiman D, Minkowitz HS, Patel SS, Boccia G; Chu A, Heiner L, Keller MR, Onel E, Ottoboni T, Quart B. HTX-011, a proprietary, extended-release combination of bupivacaine and meloxicam, reduced pain intensity and opioid consumption for 96 hours following abdominoplasty. Presented at 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting, April 2017.

Viscusi E, DeLeon-Casasola O, Gan TJ, Onel E, Boccia G, Chu A, Keller MR; Ottoboni T, Patel SS, Quart B. HTX-011, a proprietary, extended-release synergistic combination of bupivacaine and meloxicam for the relief of acute postoperative pain. Presented at 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting, April 2017.

Minkowitz HS, Winkle P, Onel E, Boccia G, Chu A, Clendeninn NJ, Keller MR, Ottoboni T, Patel SS, Quart B. Local administration of HTX-011, a long-acting biochronomer^®-based bupivacaine/meloxicam combination, in hernia repair provides similar initial results whether injected or instilled. Presented at PAINWeek, September 2016.

Winkle P, Minkowitz HS, Onel E, Boccia G, Chu A, Clendeninn NJ, Keller MR, Ottoboni T, Patel SS, Quart B. Local administration of HTX-011, a long-acting biochronomer^®-based bupivacaine/meloxicam combination, in hernia repair; preliminary results of an interim analysis. Presented at PAINWeek, September 2016

Oncology Care

CINVANTI^®

Boccia R, Geller RB, Clendeninn N, Ottoboni T. A retrospective chart review of hypersensitivity and infusion-site adverse events (ISAEs) associated with fosaprepitant IV in patients receiving anthracycline and cyclophosphamide (AC)–based chemotherapy. Accepted for presentation at Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, June 22-24, 2017, Washington DC.

Ottoboni T, Boccia G, Manhard K, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence and safety of HTX-019 (surfactant-free aprepitant IV) and fosaprepitant in healthy subjects. Accepted for presentation at Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, June 22-24, 2017, Washington DC.

Ottoboni T, Boccia G, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects. Presented at Hematology/Oncology Pharmacy Association Annual Conference, March 29-April 1, 2017, Anaheim, CA.

SUSTOL^®

Geller RB, Marks SM, Gabrail NY, Lal LS, Mujumdar U, Schwartzberg LS. Evaluation of chemotherapy-induced nausea and vomiting (CINV) events and associated resource utilization for CINV in patients (pts) treated with highly emetogenic chemotherapy (HEC) and carboplatin (Carbo) and palonosetron (palo)-based anti-emetic responses. J Clin Oncol. 2016;34 (suppl). Abstract e21649.

Geller RB, McLaughlin T, McLeod K, Bajaj M, Dakhil SR, Braun E, Chu DT, Gabrail NY, Marks SM, Schwartzberg LS. Real-world effectiveness of palonosetron with a three-drug regimen to prevent chemotherapy induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC). J Clin Oncol. 2016;34 (suppl). Abstract e18231.

Schnadig ID, Braun E, Mosier M, Geller RB, Schwartzberg LS. Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: phase 3 MAGIC trial. J Clin Oncol. 2016;34 (suppl). Abstract e21666.

Schwartzberg LS, Gabrail NY, Hrom JS, Vogelzang N, Mosier MC, Geller RB, Schnadig ID. Phase 3 MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender. J Clin Oncol. 2016;34 (suppl). Abstract e21700.

Smith C, Smith M, Holt J. APF530: A novel extended-release formulation of granisetron for 5-day prevention of chemotherapy-induced nausea and vomiting (CINV). Oncol Nurs Forum. 2016;43(2):abstr E-61. Presented at Oncology Nursing Society Congress, April 2016.

Schwartzberg L, Mosier M, Payne Y, Klepper M, Schnadig I. Phase 3 trial of APF530 vs. ondansetron, each with a neurokinin 1 antagonist and corticosteroid, for prevention of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy regimens (MAGIC Trial): Outcomes in cisplatin-based regimen. Abstract 5988, Poster 93. Presented at Society of Gynecologic Oncology Annual Meeting 2016.

Boccia R, Gabrail NY, Morrison D, Fu CH, Schnadig ID. APF530: Pharmacokinetics and efficacy of extended-release granisetron injection in the prevention of acute and delayed chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2016; vol 22(2 suppl); p17; CT20. Presented at Hematology/Oncology Pharmacy Association Annual Conference, March 2016.

Schnadig I, Agajanian R, Dakhil S, Taylor C, Wilks S, Cooper W, Mosier M, Payne Y, Klepper M, Vacirca J. Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen, for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: a post hoc subgroup analysis of the MAGIC trial. P1-10-07. Presented at San Antonio Breast Cancer Symposium, December 2015.

Schnadig I, Agajanian R, Dakhil S, Gabrail N, Smith R, Taylor C, Wilks S, Cooper W, Mosier M, Payne Y, Klepper M, Vacirca J. Phase 3 study of APF530 vs ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy–induced nausea and vomiting: MAGIC Trial. J Clin Oncol. 2015;33 (suppl 28S). Abstract 68. Presented at American Society of Clinical Oncology Breast Cancer Symposium, September 2015.

Morrison D, Anderson A, Slama M, Guernsey B, Payne Y, Fu CH, Klepper M. Phase 1 bioavailability study comparing two different subcutaneous routes of administration for APF530. Support Care Cancer. 2015; vol 23(suppl 1); S132; abstract 11-16-P. Presented at Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, June 2015.

Payne Y, Anderson A, Slama M, Guernsey B, Klepper M, Fu CH. Phase 1 bioavailability study comparing two different subcutaneous routes of administration for APF530. Oncol Nurs Forum. 2015;42(2):abstr 102. Presented at Oncology Nursing Society Congress, April 2015.

Raftopoulos H, Boccia R, Cooper W, O’Boyle E, Gralla RJ. A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron for preventing chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions? J Clin Oncol. 2014;32(suppl):abstr 9648. Presented at American Society of Clinical Oncology Annual Meeting, June 2014.

Boccia R, Cooper W, O’Boyle E. Phase 3 trial of APF530 versus palonosetron in preventing chemotherapy-induced nausea and vomiting: Efficacy in breast cancer patients receiving moderately or highly emetogenic chemotherapy. J Clin Oncol. 2014;32(suppl):abstr 9645. Presented at American Society of Clinical Oncology Annual Meeting, June 2014.

Smith C, Gabrail N. Phase 3 study comparing the efficacy and safety of sustained-release granisetron (APF530) and palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving moderately or highly emetogenic chemotherapy. Oncol Nurs Forum. 2014;41(2):abstr 34. Presented at Oncology Nursing Society Congress, April 2014.

Arevalo-Araujo R, O’Boyle E, Cooper W, Robertson P. Recovery of complete antiemetic response with APF530 during treatment with moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens in patients who failed palonosetron. J Clin Oncol. 2013;31(suppl):abstr e20569.

Barr J, O’Boyle E, Johnson M. Phase I, double-blind, placebo-controlled, ascending single subcutaneous dose, safety, tolerability, and pharmacokinetic study of sustained release granisetron (APF530). J Clin Oncol. 2013;31(suppl):abstr e20587.

Boccia R, Cooper W, O’Boyle E. Sustainability of complete responses (CRs) with APF530 (sustained-release granisetron) during multiple cycles of moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens: Results of a randomized phase III trial. J Clin Oncol. 2013;31(suppl):abstr 9626. Presented at American Society of Clinical Oncology Annual Meeting, June 2013.

Gabrail N, Yanagihara R, Cooper W, O’Boyle E, Smith C, Spaczyński M. Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results. J Clin Oncol. 2013;31(suppl):abstr e20518.

Mason J, Moon T, O’Boyle E, Dietz A. Comparison of the effects of subcutaneous APF530, intravenous granisetron, moxifloxacin, and placebo on the QT interval in humans. J Clin Oncol. 2013;31(suppl):abstr e20539.

Raftopoulos H, O’Boyle E, Gralla RJ, Rosenberg M, Barr J. The effect of continuous exposure to serotonin receptor antagonism on delayed emesis: an analysis of 1,535 patients in two randomized clinical trials with granisetron (G), APF530, and palonosetron (palo). J Clin Oncol. 2012;30(suppl):abstr e19635.

Charu V, Gabrail N, Yanagihara R, Clark-Snow R, Rosenberg MJ, O’Boyle E, Barr J. Patient satisfaction with control of emesis following chemotherapy: comparison of APF530, a subcutaneous extended-release formulation of granisetron, versus intravenous palonosetron. Support Care Cancer. 2012;20(suppl 1):abstr 1109. Presented at Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, June 2012.

Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R, Nguyen A, Robertson P, Cooper B, O’Boyle E, Barr J. Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol. 2009;27(suppl):abstr 9627. Presented at American Society of Clinical Oncology Annual Meeting, June 2009.

Barr J, O’Boyle EK, Grous JJ. Comparison of sustained-release granisetron (APF530) to a single dose of palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) following a phase III study. Abstract PA-2. Presented at Chicago Supportive Oncology Conference, 2009.

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Scientific Posters and Presentations

Acute Care

APONVIE™

ZYNRELEF®

Oncology Care

CINVANTI®

SUSTOL®

Sign-Up for Email Updates

ZYNRELEF^®

CINVANTI^®

SUSTOL^®